These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 26312447)

  • 1. Vitreous in Age-Related Macular Degeneration Therapy--The Medium Is the Message.
    Sebag J
    Retina; 2015 Sep; 35(9):1715-8. PubMed ID: 26312447
    [No Abstract]   [Full Text] [Related]  

  • 2. Anti-Vascular Endothelial Growth Factor Injection for Exudative Age-related Macular Degeneration in Patients with Vitreo-Macular Traction.
    Querques G
    Am J Ophthalmol; 2009 Feb; 147(2):375-6; author reply 376-7. PubMed ID: 19166716
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of VMA on anti-VEGF Treatment for ARMD.
    Dastiridou A; Tsironi E; Androudi S
    Ophthalmology; 2011 Nov; 118(11):2310-1; author reply 2311-2. PubMed ID: 22047905
    [No Abstract]   [Full Text] [Related]  

  • 4. Microperimetric changes after intravitreal bevacizumab for exudative age-related macular degeneration.
    Rensch F; Jonas JB
    Acta Ophthalmol; 2008 Sep; 86(6):696-7. PubMed ID: 18752522
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of vitreomacular adhesion on anti-vascular endothelial growth factor treatment for exudative age-related macular degeneration.
    Lee SJ; Koh HJ
    Ophthalmology; 2011 Jan; 118(1):101-10. PubMed ID: 20678805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age-related macular degeneration and cardiovascular disease in the era of anti-vascular endothelial growth factor therapies.
    Wong TY
    Am J Ophthalmol; 2009 Sep; 148(3):327-9. PubMed ID: 19703607
    [No Abstract]   [Full Text] [Related]  

  • 7. [New drug treatment for age-related macular degeneration].
    Stefánsson E; la Cour M; Helgadóttir G; Sigurdsson H; Jónasson F
    Laeknabladid; 2007 Apr; 93(4):299-301. PubMed ID: 17460341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravitreal bevacizumab for occult choroidal neovascularization with pigment epithelium detachment in age-related macular degeneration.
    Bom Aggio F; Eid Farah M; Melo GB
    Acta Ophthalmol Scand; 2006 Oct; 84(5):713-4. PubMed ID: 16965511
    [No Abstract]   [Full Text] [Related]  

  • 9. Tachyphylaxis and bevacizumab.
    Ziemssen F; Neuhann IM; Voelker M
    Ophthalmology; 2009 Aug; 116(8):1591-2; author reply 1592-3. PubMed ID: 19651319
    [No Abstract]   [Full Text] [Related]  

  • 10. Tachyphylaxis and bevacizumab.
    Avgikos KN; Horgan SE; Sivaraj RR; Hu K
    Ophthalmology; 2009 Sep; 116(9):1831-2; author reply 1832. PubMed ID: 19729101
    [No Abstract]   [Full Text] [Related]  

  • 11. Bevacizumab tachyphylaxis.
    Falavarjani KG; Modarres M
    Ophthalmology; 2009 May; 116(5):1016-7; author reply 1017. PubMed ID: 19410964
    [No Abstract]   [Full Text] [Related]  

  • 12. INFLUENCE OF VITREOMACULAR INTERFACE ON ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY USING TREAT AND EXTEND TREATMENT PROTOCOL FOR AGE-RELATED MACULAR DEGENERATION (VINTREX).
    Houston SK; Rayess N; Cohen MN; Ho AC; Regillo CD
    Retina; 2015 Sep; 35(9):1757-64. PubMed ID: 26110596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors associated with spontaneous release of vitreomacular traction.
    Almeida DR; Chin EK; Rahim K; Folk JC; Russell SR
    Retina; 2015 Mar; 35(3):492-7. PubMed ID: 25207947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subretinal tissue plasminogen activator injection to treat submacular haemorrhage during age-related macular degeneration.
    Dewilde E; Delaere L; Vaninbroukx I; Van Calster J; Stalmans P
    Acta Ophthalmol; 2014 Sep; 92(6):e497-8. PubMed ID: 24943231
    [No Abstract]   [Full Text] [Related]  

  • 15. Intravitreal avastin: the low cost alternative to lucentis?
    Rosenfeld PJ
    Am J Ophthalmol; 2006 Jul; 142(1):141-3. PubMed ID: 16815262
    [No Abstract]   [Full Text] [Related]  

  • 16. Vitreomacular traction in a case of exudative age-related macular degeneration resistant to anti-VEGF therapy.
    Shah SU; Haller JA
    Acta Ophthalmol; 2012 Nov; 90(7):e569-70. PubMed ID: 22429537
    [No Abstract]   [Full Text] [Related]  

  • 17. Intravitreal VEGF-inhibitors: is Avastin a generic substitute for Lucentis?
    la Cour M
    Acta Ophthalmol Scand; 2007 Feb; 85(1):2-4. PubMed ID: 17244202
    [No Abstract]   [Full Text] [Related]  

  • 18. The as-needed treatment strategy for choroidal neovascularization: a feedback-based treatment system.
    Spaide RF
    Am J Ophthalmol; 2009 Jul; 148(1):1-3. PubMed ID: 19540983
    [No Abstract]   [Full Text] [Related]  

  • 19. Controversies in the treatment of wet age-related macular degeneration.
    Moreno SF; Paloma JB
    Am J Ophthalmol; 2008 May; 145(5):937; author reply 938. PubMed ID: 18435977
    [No Abstract]   [Full Text] [Related]  

  • 20. VITREOMACULAR TRACTION AFFECTS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT OUTCOMES FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION.
    Krishnan R; Arora R; De Salvo G; Stinghe A; Severn PS; Pal B; Goverdhan S
    Retina; 2015 Sep; 35(9):1750-6. PubMed ID: 26237240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.